SOAT1 and acute myeloid leukemia: Secondary AML development following myeloproliferative neoplasms driven by aberrant JAK/STAT signaling—typically resulting from the JAK2 V617F mutation—has been recently characterized as displaying decreased interferon signaling and increased LSC-specific transcriptome signatures.76